Cardiff Oncology, Inc. (CRDF)
NASDAQ: CRDF · Real-Time Price · USD
2.850
+0.040 (1.42%)
Apr 17, 2025, 4:00 PM EDT - Market closed
Cardiff Oncology Revenue
In the year 2024, Cardiff Oncology had annual revenue of $683.00K with 39.96% growth. Cardiff Oncology had revenue of $151.00K in the quarter ending December 31, 2024, a decrease of -3.21%.
Revenue (ttm)
$683.00K
Revenue Growth
+39.96%
P/S Ratio
198.84
Revenue / Employee
$20,697
Employees
33
Market Cap
189.59M
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 683.00K | 195.00K | 39.96% |
Dec 31, 2023 | 488.00K | 102.00K | 26.42% |
Dec 31, 2022 | 386.00K | 27.00K | 7.52% |
Dec 31, 2021 | 359.00K | -7.00K | -1.91% |
Dec 31, 2020 | 366.00K | 121.37K | 49.61% |
Dec 31, 2019 | Pro | Pro | Pro |
Dec 31, 2018 | Pro | Pro | Pro |
Dec 31, 2017 | Pro | Pro | Pro |
Dec 31, 2016 | Pro | Pro | Pro |
Dec 31, 2015 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 410.06B |
Johnson & Johnson | 89.33B |
Merck & Co. | 64.17B |
AbbVie | 56.33B |
AstraZeneca | 54.07B |
Novartis AG | 51.72B |
Eli Lilly and Company | 45.04B |
Thermo Fisher Scientific | 42.88B |
CRDF News
- 3 days ago - Cardiff Oncology Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewsWire
- 3 days ago - Cardiff Oncology Announces Completion of Enrollment in Phase 2 CRDF-004 Trial Evaluating Onvansertib for the Treatment of First-line RAS-mutated Metastatic Colorectal Cancer - GlobeNewsWire
- 7 weeks ago - Cardiff Oncology, Inc. (CRDF) Q4 2024 Earnings Call Transcript - Seeking Alpha
- 7 weeks ago - Cardiff Oncology Reports Fourth Quarter and Full Year 2024 Results and Provides Business Update - GlobeNewsWire
- 7 weeks ago - Cardiff Oncology to Present at Upcoming Investor Conferences - GlobeNewsWire
- 2 months ago - Cardiff Oncology to Report Fourth Quarter 2024 Results and Provide Business Update - GlobeNewsWire
- 2 months ago - Cardiff Oncology: Pioneering RAS-Mutated Cancer Therapies With Onvansertib - Seeking Alpha
- 4 months ago - Undercovered Dozen: Ubiquiti, Ready Capital, Cardiff Oncology, Vodafone + - Seeking Alpha